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 Abstract:  We report on two areas in which UK law and ethics seem out of step with each 
other. 2013 saw the passing of the Transplantation (Wales) Bill, which will introduce an opt-
out system of organ donation in Wales from 2015. In the fi rst section, we discuss the convo-
luted evolution of the bill and some potential problems that we consider may prevent it 
from achieving its intended goal of increasing the number of organs transplanted. The 
prospect of being able to enhance human cognition through cognitive-enhancing drugs 
(“smart drugs”) also presents a nexus of questions associated with future ambitions, hopes, 
and concerns as a society. How these drugs might affect the future of work and employ-
ment is beginning to generate wide public engagement in the UK and forms the focus of the 
second section. 
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 Law and ethics, as in many intimate relationships, can easily get out of step with 
each other. We report on two areas in medicine in which this seems to have hap-
pened recently in Britain. In the case of organ donation, remarkable progress has 
been made over the past fi ve years in improving the number of organs available 
for transplant in the UK, yet Wales has insisted on legislating for change in its 
law, which could lead to unethical practice and could jeopardize what has been 
achieved so far. In the use of cognitive-enhancing drugs, however, legislation is 
lagging well behind current trends in social behavior, and ethical analysis of “mind 
enhancement” is progressing well in advance of UK law. 
 The Transplantation (Wales) Bill 2013 
 The United Kingdom  1  looks set soon to be divided over organ transplantation. 
Currently the whole of the UK operates an opt-in system of organ donation for 
transplantation from dead donors. The Human Tissue Act (HTA) 2004 makes 
“lawful if done with appropriate consent”  2  both the removal and the use “from 
the body of a deceased person, for use for a purpose specifi ed in Schedule 1 
[including transplantation  3  ], of any relevant material of which the body consists 
or which it contains.”  4  The “appropriate consent” is usually considered as given 
by joining the organ donor register  5  maintained by NHS (National Health Service) 
Blood and Transplant (NHSBT) organization. However, as two recent books on 
the ethics of organ acquisition have clearly demonstrated, though there is in fact 
no direct ethical requirement in the UK to obtain express consent of either the 
deceased or their relatives before taking organs after death,  6  “there is clearly a 
deep feeling that  someone should give positive consent for organ retrieval.”  7  
 On July 2, 2013, the National Assembly of Wales voted to adopt what they 
describe as “a soft opt-out system for consent to deceased organ and tissue dona-
tion in Wales from 2015.”  8  When implemented, this will be a landmark change in 
QA
Trevor Stammers and Matt James
2
transplantation policy (and possibly practice) in Wales, and the recent political 
background to the vote is worth recounting. 
 Organ Donation Law in the UK 
 In 2006–7 there were just more than 14 million people on the NHS Organ Donor 
Register, and though 3,000 transplants were carried out, 1,000 people died while 
still on the waiting list.  9  At that time, the government commissioned the UK Organ 
Donation Task Force, which reported in 2008  10  and set a target of increasing the 
number of organs for donation after death in the UK by 50 percent by 2013, an 
ambitious target that was nevertheless achieved earlier this year.  11,12  A change from 
the current opt-in system, however, had not been among the 14 recommendations 
made in the report, which focused instead on issues concerning donor identifi ca-
tion and referral, donor coordination, and organ retrieval. 
 In 2010, however, the task force produced another report specifi cally examining 
the introduction of an opt-out system in the UK. It concluded that the issue was 
“fi nely balanced,” with several factors supporting a change—for example, opin-
ion polls revealed 60 percent pubic support for the idea—but also considerable 
evidence “highlighting the potential downside of such a move.”  13  The task force 
commented “that moving to an opt out system . . . may deliver real benefi ts but 
carries a signifi cant risk of making the current situation worse,” for example, by 
damaging “the vital relationship of trust between clinicians caring for people at 
the end of life, their patients and their families.”  14  They concluded they were “not 
confi dent that the introduction of opt-out legislation would increase organ dona-
tion, and there is evidence that donor numbers may go down.”  15  
 The UK’s highly infl uential Nuffi eld Council on Bioethics also produced a 
consultation paper in 2010 on ethical issues concerning the use of human tissue, 
including consent for postmortem transplantation, the responses to which informed 
their defi nitive 2011 report,  Human Bodies .  16  The working party for that report 
commissioned a review of donation legislation in other countries,  17  including 
opt-out arrangements, and concluded that “in practice such systems differed 
less than might be imagined from the ‘opt-in’ system in the UK.”  18  In particu-
lar they noted that in Spain, which has the highest donation rates in Europe, 
“there is no requirement to express opposition to organ donation in any par-
ticular form, and hence it is standard practice to seek ‘consent’ from the family.”  19  
The Nuffi eld report made no recommendation to change to an opt-out system 
in the UK, a view still currently taken by the Department of Health, perhaps 
not surprisingly, because the most recent fi gures for the year ending March 31, 
2013,  20  show a total of 4,111 organ transplants, of which 3,112 were from dead 
donors—an increase of 6.8 percent on the previous year, with a corresponding 
reduction of the waiting list of more than 3 percent, to 7,532. There were just 
more than 19.5 million people on the organ donor register by the end of March 
2013 21 —a rise of 22 percent in fi ve years. 
 The Evolution of the Transplantation (Wales) Bill 2013 
 In 2007, the NHS Wales published  Designed to Tackle Renal Disease in Wales: A 
National Service Framework .  22  The section on transplantation aimed to fi nd “ways 
to try and improve the donation rate from both living and cadaveric donors, and 
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to provide guidance on how each donated kidney can be used to its maximum 
potential.”  23  Its fi rst proposed key intervention was “to increase public awareness 
of the need for organ donation, to encourage people to enrol on the organ donor 
register and to make their wishes known to those close to them”; no mention was 
made of introducing an opt-out system.  24  In July 2008, the Welsh Health, Well-
Being and Local Government Committee produced a report entitled  Inquiry into 
Presumed Consent for Organ Donation . It concluded,
 The most urgent and productive steps for improving donation rates rest 
with the early implementation in Wales of the UK Organ Donation Task 
Force (ODTF) recommendations. We do not rule out introducing pre-
sumed consent in Wales at some point in the future. However, we do not 
believe that it is currently the most urgent priority and believe that it 
could be a distraction from other, more productive actions.  25  
 Despite the lack of evidence supporting introducing an opt-out system in Wales, 
in October 2008 the Welsh Assembly launched a public discussion document  26  on 
an opt-out proposal. By September 2009, the Assembly’s report on the responses 
received to the consultation concluded, “The majority of responses supported a 
change to the organ donation consent system in Wales to a soft opt-out system” 
(p. 6). This eventually led to a white paper in November 2011 proposing the opt-out 
legislation, which has now been adopted in the bill. 
 While all the activity was underway regarding the introduction of presumed 
consent, the implementation of the 2008 ODTF-recommended strategies resulted 
in a 91 percent increase in organ donation rates in Wales from 2008–9 to 2011–
12 27 —way in excess of the goal of 50 percent set by the ODTF for the whole of the 
UK. Furthermore, though the latest fi gures for 2012–13 show a rise of 20 percent in 
the number of donations in the UK overall,  28  the number in Wales fell by 12 per-
cent (to 211) in the previous year  29  —the year during which donation in Wales had 
been discussed more than in the rest of the UK, with all the public consultation 
concerning the Welsh Bill. 
 Ambivalence over Opt-Out Policies 
 The bill’s soft opt-out policy is explained by the Welsh Assembly as follows: 
“A person’s consent to donation will be deemed to have been given unless they 
objected during their lifetime—a process called opting out—but where those closest 
to the deceased will still have an important role to play in the process.”  30  However, 
exactly what that role is is very far from clear. The text of the bill does allow for 
relatives to object to organ acquisition when “(a) a relative or friend of long stand-
ing of the deceased objects on the basis of views held by the deceased, and (b) a 
reasonable person would conclude that the relative or friend knows that the most 
recent view of the deceased before death on consent for transplantation activities 
was that the deceased was opposed to consent being given.”  31  However, a soft 
opt-out system is generally understood as one in which the relatives have the right 
of veto over donation if the deceased’s wishes were unknown or disputed.  32  The 
Transplantation (Wales) Bill, as passed, has the potential to be interpreted in prac-
tice as a hard opt-out system—a system in which organs may be taken against the 
relatives’ wishes; this system currently operates in Austria  33  but had to be repealed 
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when introduced in Brazil  34  and was rapidly revised in Chile  35  because it had a 
deleterious effect on donation rates. In Singapore, which extended a hard opt-out 
system to include liver, heart, and corneas in 2005, the rate of 5.9 deceased organ 
donors per million population in that year fell by 22 percent, to just 4.6 per million 
by 2009.  36  Much of this fall was probably related to the public reaction to the dis-
tressing case of Sim Tee Hua in 2007.  37  When an opinion piece advocating a hard 
opt-out system in the UK was published very recently in the  BMJ ,  38  not a single 
one of the responses submitted online agreed with the author’s view.  39  
 The Inﬂ uence of the Welsh Bill on the Whole UK 
 Though the Welsh Bill is not due to be implemented in Wales until 2015, it has 
already prompted moves toward similar changes in other parts of the UK. Two 
early day motions to introduce a nationwide opt-out system were tabled in the 
Westminster Parliament in the autumn of 2011,  40,41  one of which specifi cally 
referred to the Welsh initiative. The British Medical Association, which has for 
some time been in favor of the introduction of an opt-out system,  42  immediately 
hailed the “opt-out organ donation law as one of the most important pieces of 
legislation in Welsh history.”  43  A week after the passing of the Welsh Bill, a BBC 
article claimed that “the NHS is considering preventing families from overriding 
the consent of people who have signed the organ donor register.”  44  In it, the direc-
tor of the NHSBT was reported as asking, “Is it right to allow our organs to be 
buried or cremated with us when they could save or improve the lives of up to 
nine people?” 
 In Scotland, the  Glasgow Evening Times , which for several years has been run-
ning the infl uential Opt for Life campaign to introduce an opt-out system, imme-
diately urged the Scottish Parliament to follow Wales’ lead, and Drew Smith, a 
member of the Scottish Parliament, pledged to introduce a member’s bill to this 
effect if the Parliament does not act.  45  Finally, in Northern Ireland, Jo-Anne Dobson, 
the mother of a successful transplant patient and a member of the Stormont 
Assembly, is planning to introduce a private members bill to introduce an opt-out 
system in the province.  46  
 We consider it likely that when, or even before, the Welsh Bill is enacted in 2015, 
both pragmatic border issues and political momentum will mean that the whole of 
the UK will eventually follow suit. The Welsh Bill’s arrangements regarding Welsh 
residents who die in other parts of the UK and other permutations regarding resi-
dency  47  are so complex that the implementation of them will be both costly and 
diffi cult, especially when relatives cannot be contacted. Though there is a large 
transplantation center in Cardiff, where most patients in South Wales are treated, 
those living in North Wales often have their transplants carried out in England. 
Though the diffi culties of differing legislation in the two regions are not insuperable, 
clearly there will be enormous pressure to unify the position throughout the UK. 
 Given that the introduction of the opt-out system and the opt-in register will 
have to be run in parallel for many years and also that the Welsh Assembly consid-
ers that the whole population will need to be fully informed about the possibility 
and practicalities of opting out, it will be a slow and costly procedure. Its promised 
benefi ts are by no means certain in the light of international experience as a 
whole.  48  Trust is a delicate moral fabric and not easily restored when damaged; 
if the Welsh Bill is interpreted and practiced as a hard opt-out system, public 
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confi dence in the NHS transplant system as whole could be undermined. As trans-
plant surgeon Dorry Sergev recently commented, “With opt-out the perception 
becomes, ‘We will take your organs unless you take the time to fi ll out a form.’ 
That’s a dangerous perception to have.”  49  We consider it advisable to see what 
happens fi rst to organ donation rates in Wales from 2015 to 2020 before extending 
an opt-out system to other parts of the UK. 
 “Smart Drugs” 
 Public discussion concerning the use of cognitive-enhancing “smart drugs” (noo-
tropics) is intensifying in the UK 50,51,52 as more people experiment with them. 
A poll by Cambridge University’s  Varsity newspaper revealed that 1 in 10 students 
use cognition-enhancing drugs such as modafi nil, whereas 1 in 3 said that they 
would take concentration-enhancing medication if offered the opportunity.  53  
 Data have revealed that the number of stimulants prescribed in England has 
been rising steadily from 220,000 in 1998 to 418,300 in 2004.  54  In November 2011, 
the BBC’s  Newsnight program ran an anonymous online questionnaire that sought 
to gather data on the use of cognitive-enhancing drugs. Of the 761 people who 
replied, 38 percent said they had taken cognitive-enhancing drugs, 40 percent said 
they had bought the drugs online, and 92 percent said that they would use them 
again.  55  On the global scale, an online issue of  Nature indicated that, of 1,400 
respondents from 60 countries, 1 in 5 said that they had used drugs for nonmedi-
cal reasons as a cognitive enhancer.  56  
 This is not an issue of which the UK government is unaware. Its horizon-scanning 
and future-planning center, Foresight, has predicted that “pharmacological enhance-
ment of cognition in both the young and old healthy populations seems set to 
become increasingly popular, extending from dietary supplements and caffeine to 
drugs specifi cally targeted at improving cognition.”  57  
 The Impact of Smart Drugs on the Workforce and Work Culture 
 The prospect of being able to enhance human cognition presents a nexus of ques-
tions associated with future ambitions, hopes, and concerns as a society. One way 
of framing this debate, which is beginning to generate wide public engagement 
in the UK, is by looking at the impact of smart drugs on the workforce and working 
conditions. In an economic climate causing us to assess how to generate more with 
less, the attraction of working longer hours but with increased levels of concen-
tration and stamina is obvious. Because people need to continue working later 
in their lives—leading to a heightened risk of age-related memory loss—could 
cognitive-enhancing drugs be part of the answer? Accidents in the workplace 
can often be attributed to employees loosing concentration, so could safety in the 
workplace also be improved through the use of cognitive-enhancing drugs, irre-
spective of the age of the employee? In America, modafi nil is already used among 
shift workers in order to reduce accidents.  58  
 The Work Foundation has recognized the potential cognitive-enhancing drugs 
may well have in the workforce, suggesting that perhaps the next great leap in 
terms of work culture is using these drugs to improve concentration, to allow us 
to work without sleep, to minimize impulsivity, and to improve planning and 
development of ideas.  59  In fact, the Work Foundation chose this subject as the 
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focus of its annual debate in 2013,  60  demonstrating the importance they attribute 
to such developments. 
 Similarly,  Human Enhancement and the Future of Work , a recent report by some of the 
UK’s most respected science institutions—the Academy of Medical Sciences, the 
British Academy, the Royal Academy of Engineering, and the Royal Society—also rec-
ognizes the very real possibility of cognitively enhanced, super-alert workers in the 
future. In reviewing new technologies, the report found that “work will evolve over 
the next decade, with enhancement technologies potentially making a signifi cant 
contribution.”  61  The report goes on to comment that in the specifi c case of cognitive-
enhancing drugs, they could be used to “treat individuals with neuropsychiatric 
disorders [and] could also improve mental faculties such as memory and concentra-
tion in healthy individuals, enabling them to work more effi ciently or for longer.”  62  
 Experts report that experiencing a decline in cognitive abilities is very often the 
reason why many people are not able to return to work after having experienced 
episodes of depression and schizophrenia. Cognitive-enhancing drugs can help to 
treat these kinds of disabilities while simultaneously improving mental capacity 
and well-being. Current estimates indicate that by 2026 the cost of mental health 
disorders in England will rise to £88.4 billion, nearly half of which will be as a 
result of lost earnings (£40.9 billion).  63  There are therefore clear economic benefi ts 
to investing the development of treatments for neuropsychiatric disorders in the 
working population. 
 But on the other hand, at what cost are we attaining this increased concentra-
tion? Are we increasing work productivity at the expense of quality of life? Could 
creativity, which generally requires relaxation and the loosening of mental con-
centration, actually be lost rather than improved in light of the fact that concen-
tration is heightened through the use of cognition enhancing drugs? Research to 
date yields a mixture of results on this point,  64  but there is evidence to suggest 
that there are limits to the effectiveness of such drugs and that it depends on the 
baseline creativity of an individual. Cognitive-enhancing drugs may help to raise 
creativity in lower-performing individuals while inhibiting it in naturally high-
performing individuals.  65  Nevertheless, there are genuine concerns over the kind 
of society that could be created if the use of cognitive-enhancing drugs became 
more widespread. Would we use these drugs to make work more rewarding and 
effi cient, which in turn would afford us more opportunities to enjoy life and take 
up more hobbies and recreational pursuits? Or would we take the opportunity 
to work more and for longer, creating an accelerated, 24/7 work culture? Will 
employees face being coerced into using cognitive-enhancing drugs in order to 
keep their jobs, or to even be offered a job in the fi rst place? If steps are taken to 
enhance older workers, will this negatively affect younger people trying to fi nd 
work? And on a wider perspective, could the use of cognitive-enhancing drugs 
drive forward the competiveness of user countries within the global village, 
forcing other countries to consider national enhancement programs in order to 
maintain their competitive edge? 
 The Regulation of Smart Drugs 
 Discussion of national programs leads on to policy and regulatory issues. Currently 
little is known either about user habits or of the longer-term side effects of taking 
smart drugs. The advent of the Internet has provided a ubiquitous means through 
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which individuals, in the comfort and privacy of their own homes, can purchase 
smart drugs, helping to shape a “closet phenomenon.”  66  In order to responsibly 
address the issue of these drugs, the topic needs to be brought out into the open 
and proactively engaged with, rather than being merely ignored or dismissed as 
the activity of a select minority. 
 An isolated discussion, devoid of public involvement, can be dangerous for 
industry, risking the possibility of a public reaction like that which emerged 
following the genetically modifi ed (GM) crops issue. Early upstream engagement 
is essentially in order to garner not only public opinion but also public confi -
dence in future developments. This in turn will help to shape and direct eco-
nomic decisionmaking. 
 In terms of specifi c legislation of cognitive-enhancing drugs, there are no UK 
frameworks currently in place, although we do know that the drugs remain 
strictly off license in both the UK and the United States.  67  This presents the ques-
tion of how these drugs will be obtained and distributed. The UK’s Foresight 
project acknowledged that the current regulatory processes may not be adequate 
to effectively manage the potential ready availability of cognition enhancers.  68  
In 2009, the UK Home Offi ce asked the Advisory Council on the Misuse of Drugs 
to see how this “rapidly evolving fi eld” should be regulated amid fears from 
medical experts that the range of drugs available could fuel an overcompetitive 
society when used by the healthy.  69  There is a real need for the government to 
build on such work and to help to increase consultation on these issues and 
develop a long-term strategy for public engagement on this issue. 
 Crucial to any regulatory model for the use of drugs for enhancement by healthy 
people is the issue of safety. Cognitive-enhancing drugs have been primarily 
developed for those people suffering from neuropsychiatric disorders and brain 
injuries. Consequently, there is a lack of long-term safety studies of these drugs 
and their effects on healthy people. How should the risks of using these drugs be 
mitigated? In order to assess these risks, regulators would need long-term data 
and safety studies in order to base their decision as to whether or not to extend 
their licenses. Leadership is needed on this issue, as pharmaceutical companies do 
not appear to be responding with appropriate action to instigate such studies. 
Cognitive enhancers such as Ritalin are classifi ed in the UK as a controlled drug, 
whereas modafi nil is not, thus making it legal to buy the latter online, though still 
illegal to supply it without a prescription.  70  Using the Internet to procure drugs in 
this way always presents problems, not least in terms of authenticating the source 
from which you are purchasing as well as simply trying to enforce regulation on a 
medium that transcends geographical borders. The UK Medicines and Healthcare 
Products Regulatory Agency (MHRA), part of the UK government’s regulation 
and safeguarding arm of its healthcare system, has made the matter of the illegal 
sale and supply of medicines over the Internet a priority.  71  
 Do Smart Drugs Promote Human Well-Being? 
 Talk of any form of human enhancement often quickly leads to questions concern-
ing the creation of a social divide between the haves and have-nots. The economist 
Fred Hirsch has argued that the pursuit of what he terms “positional goods” 
should be discouraged. These goods accrue value only because only some people 
have them, whereas others do not. If society as a whole pursued positional goods, 
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it would be a waste of time and resources. As Hirsch neatly puts it, “if everyone 
stands on tiptoe, no one sees any better.”  72  Improved cognitive functioning has 
been argued to bring with it nonpositional benefi ts. Bostrom and Roache report 
that economic models of the fi nancial loss caused by small intelligence decrements 
due to lead in drinking water demonstrate signifi cant economic effects with a 
decline of only a few points in IQ scores.  73  Thus, signifi cant benefi ts could be 
expected if a small amount of intelligence was in fact gained by only part of soci-
ety “enhancing” itself. Improving cognition could therefore bring not only benefi ts 
to the individual but also cultural and economic benefi ts to society as a whole.  74  
 The idea of the human condition being one of continuing to seek improvement of 
itself may be true to a certain extent. Nevertheless, could it also be argued that what 
makes us human is our variety without conformity. Every effort should be made to 
alleviate suffering and disease, but at the same time we must keep in balance the 
real value of forms of enhancement. However, this line of argument assumes that 
there is a discoverable boundary between health and illness—something that is not 
easy to establish. Some would even argue that such a boundary does not exist. 
Thus the therapy/enhancement paradigm does not seem to provide an adequate 
response to the most pertinent questions that seem to be of primary concern: that 
of inequity, abuse, and control. 
 These kinds of concerns were noted in the High-Level Expert Group report from 
the European Commission,  75  with reference to the prospect of the “pursuit of hap-
piness.” The EU report argued that there should not be “engineering  of the mind 
and  of the body” but rather “engineering  for the mind and  for the body,” which 
would somehow maximize our humanity without taking us beyond it. Although 
helpful, critics have attacked this distinction by pointing out that it presupposes 
that a bright line can be clearly drawn between peripheral technologies—external 
tools and aids that may augment function and the underlying hardware. Bostrom 
and Roache suggest that we move away from a therapy, disease-focused framework 
and adopt instead an approach (particularly in terms of regulation) that focuses 
more on human well-being.  76  A benefi t of pursuing this path could be to help 
facilitate the much-needed regulation of the development of cognitive-enhancing 
drugs for use by healthy adults. 
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